Vertex Pharmaceuticals (VRTX) Profit After Tax (2009 - 2026)

Vertex Pharmaceuticals' Profit After Tax history runs 18 years deep, the most recent figure standing at $1.0 billion for Q1 2026.

• In Q1 2026, Profit After Tax rose 59.59% year-over-year to $1.0 billion; the TTM figure through Mar 2026 stood at $4.3 billion (up 538.7% YoY), while the FY2025 annual figure was $4.0 billion, up 838.09% from the prior year.
• Profit After Tax for Q1 2026 stood at $1.0 billion, down from $1.2 billion in the prior quarter.
• The five-year high for Profit After Tax was $1.2 billion in Q4 2025, with the low at -$3.6 billion in Q2 2024.
• The 5-year median for Profit After Tax is $930.5 million (2022), against an average of $670.0 million.
• The sharpest annual moves came in 2022 and 2024: Profit After Tax soared 1109.7% in 2022, then slumped 492.44% in 2024.
• Vertex Pharmaceuticals' Profit After Tax stood at $818.9 million in 2022, then grew by 18.31% to $968.8 million in 2023, then retreated by 5.76% to $913.0 million in 2024, then soared by 30.46% to $1.2 billion in 2025, then declined by 13.41% to $1.0 billion in 2026.
• Business Quant data shows VRTX's Profit After Tax at $1.0 billion in Q1 2026, $1.2 billion in Q4 2025, and $1.1 billion in Q3 2025.